Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41337590.
- Also identified by DOI 10.1126/sciadv.aea6124 and PMC identifier 12674112.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Carcinogenesis in human urothelium is driven by a high burden of mutations caused by the antiviral "APOBEC3" (apolipoprotein B mRNA editing enzyme, catalytic subunit-like 3) cytosine deaminase enzymes; however, there is no established viral etiology. BK polyomavirus (BKPyV) is a ubiquitous childhood infection that persists in the kidney during adulthood and is frequently detected in urine. Chronic BKPyV infections of normal human urothelium induced an innate response, including apical extrusion of infected cells. Local paracrine interferon signaling induced APOBEC3 expression in both infected and juxtaposed bystander cells, leading to acquisition of hallmark APOBEC3-mediated mutational signatures that recapitulated the variation in mutational character found in patients with muscle-invasive bladder cancer. In our model for urothelial carcinogenesis, uninfected bystander cells witnessing BKPyV infection become APOBEC3 damaged, escape extrusion, and acquire hypermutable advantage. "Transmutagenesis" explains how cells proximal to infected neighbors acquire cancer-initiating mutations. This hypothesis for how urothelial cancers can develop as APOBEC3 signature rich, while remaining virus-negative, suggests that a large proportion of urothelial carcinomas may be preventable by antiviral intervention.
Medical subject headings
- BK Virus
- Cytidine Deaminase
- Mutation
- Polyomavirus Infections
- Tumor Virus Infections
- Urinary Bladder Neoplasms